BioSpace News Archive

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter and full year 2022 results on Wednesday, March 1, 2023.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes.

Edesa Biotech, Inc. today announced that it has received approval from Health Canada for a Phase 2 clinical study of the company’s EB06 monoclonal antibody candidate as a treatment for vitiligo.

Pardes Biosciences, Inc. announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 10:40 a.m. PT / 1:40 p.m. ET.

Ratio Therapeutics Inc. announces the close of its Series A financing extension today, bringing the total raised to date to over $40 million.

RespireRx Pharmaceuticals Inc. is pleased to announce that, on January 27, 2023, ResolutionRx Ltd, a newly formed Australian unlisted public company, and initially, a wholly-owned subsidiary of RespireRx, entered into a Letter of Intent and Term Sheet with Radium Capital.

Gilead Sciences, Inc. (Nasdaq: GILD) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity (THE) Oncology Grant™.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Breast Cancer were updated to include an addition involving neratinib (NERLYNX ® ).

Neovasc, Inc. announced the German Institute for the Hospital Remuneration System has awarded the Neovasc Reducer™, a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B infection (CHB).